Back to EGF+61 genetic polymorphisms and lung cancer risk

looking to the future!

Authors

  • Ramon Andrade De Mello University of Porto

Downloads

Download data is not yet available.

Author Biography

Ramon Andrade De Mello, University of Porto

MD. Medical Oncology Resident in the Department of Medical Oncology, Portuguese Oncology Institute, Porto, Portugal; and Assistant Professor in the School of Medicine, Department of Medicine, University of Porto, Porto, Portugal.

References

Hu-Lieskovan S, Vallbohmer D, Zhang W, et al. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients. Clin Cancer Res. 2011;17(15):5161-9.

Lim YJ, Kim JW, Song JY, et al. Epidermal growth factor gene polymorphism is different between schizophrenia and lung cancer patients in Korean population. Neurosci Lett. 2005;374(3):157-60.

Kang HG, Choi JE, Lee WK, et al. +61A>G polymorphism in the EGF gene does not increase the risk of lung cancer. Respirology. 2007;12(6):902-5.

de Mello RA, Ferreira M, Costa BM, et al. Association between +61 A/G polymorphism in the EGF gene and non-small cell lung cancer risk in male caucasians. Eur J Cancer. 2011;47(Suppl 1):S635. [poster 9139].

Zhang YM, Cao C, Liang K. Genetic polymorphism of epidermal growth factor 61A>G and cancer risk: a meta-analysis. Cancer Epidemiol. 2010;34(2):150-6.

Downloads

Published

2012-11-11

How to Cite

1.
Mello RAD. Back to EGF+61 genetic polymorphisms and lung cancer risk: looking to the future!. Sao Paulo Med J [Internet]. 2012 Nov. 11 [cited 2025 Mar. 14];130(6):415-6. Available from: https://periodicosapm.emnuvens.com.br/spmj/article/view/1514

Issue

Vol. 130 No. 6 (2012)

Section

Letter to the Editor

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.